Repurposing Epalrestat: Direct KEAP1/Nrf2 Activation in Parkinson’s Disease Models

Study Background and Research Question

Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by the degeneration of dopaminergic (DAergic) neurons in the substantia nigra, resulting in characteristic motor and non-motor symptoms. While current PD therapies primarily focus on symptomatic relief through dopamine replacement, they do not halt disease progression or address the underlying molecular pathology, which is increasingly linked to oxidative stress and mitochondrial dysfunction. As the global prevalence of PD rises—affecting over 8.5 million people in 2019—there is a growing need for disease-modifying interventions (Jia et al., 2025).

Epalrestat, an aldose reductase inhibitor, is clinically approved for treating diabetic neuropathy by targeting the polyol pathway. Preliminary studies have suggested that Epalrestat may also exert neuroprotective effects through antioxidant mechanisms, but its precise actions in central nervous system diseases such as PD have remained unclear. The central research question in Jia et al. (2025) is whether Epalrestat can suppress PD progression and by what molecular mechanisms, specifically investigating its effects on the KEAP1/Nrf2 pathway in both cellular and animal PD models.

Key Innovation from the Reference Study

The innovation in Jia et al. (2025) lies in the direct demonstration that Epalrestat competitively binds to KEAP1, enhancing KEAP1 degradation and thereby activating the Nrf2 antioxidant signaling pathway. While the role of the KEAP1/Nrf2 pathway in cellular defense against oxidative stress has been well established, this study is the first to provide molecular evidence that a clinically available aldose reductase inhibitor can directly target KEAP1 for neuroprotection in PD models. Importantly, this finding bridges the gap between Epalrestat’s established role in diabetic neuropathy research and its emerging relevance in neurodegenerative disease models.

Methods and Experimental Design Insights

Jia et al. employed a rigorous combination of in vitro and in vivo models to probe Epalrestat’s neuroprotective effects and underlying mechanisms. The main experimental strategies included:

• Use of MPP⁺-treated cells and MPTP-treated mice to model PD-related neurodegeneration.
• Oral administration of Epalrestat three times daily, initiated three days before PD model establishment and continued for five consecutive days.
• Behavioral assessments of motor function using open field, rotarod, and CatWalk gait analysis in mice.
• Immunofluorescence to assess DAergic neuron survival in the substantia nigra.
• Quantification of oxidative stress markers and mitochondrial function metrics.
• Molecular biology techniques—including Western blot, qPCR, and immunostaining—to analyze KEAP1/Nrf2 pathway activity.
• Molecular docking, surface plasmon resonance, and cellular thermal shift assays to confirm direct Epalrestat-KEAP1 interactions.

This multifaceted experimental design allowed for both phenotypic and mechanistic insights into Epalrestat’s actions in PD models.

Protocol Parameters

• Epalrestat pretreatment: Begin administration 3 days before PD model induction; continue for 5 days with oral dosing three times daily.
• PD model induction: Use MPTP for in vivo (mouse) models and MPP⁺ for in vitro cell systems to replicate PD-like dopaminergic neurodegeneration.
• Behavioral testing: Conduct open field, rotarod, and CatWalk gait analyses to quantify motor deficits and therapeutic effects.
• Assessment of neuronal survival: Perform immunofluorescence on substantia nigra tissue to count DAergic neurons.
• Oxidative stress and mitochondrial function: Measure ROS levels, mitochondrial membrane potential, and Nrf2 target gene expression as readouts for pathway activation.

Core Findings and Why They Matter

Jia et al. found that Epalrestat administration led to significant improvements in behavioral outcomes and DAergic neuron survival in both in vivo and in vitro PD models. Notably, Epalrestat treatment:

• Reduced markers of oxidative stress and alleviated mitochondrial dysfunction in PD models.
• Activated Nrf2 signaling, as evidenced by increased Nrf2 nuclear translocation and upregulation of antioxidant target genes.
• Directly bound KEAP1, leading to its enhanced degradation, which in turn relieved Nrf2 inhibition.

These results provide compelling evidence that Epalrestat’s neuroprotection in PD is mediated by direct modulation of the KEAP1/Nrf2 axis, positioning it as a promising candidate for disease-modifying therapy beyond its established use in diabetic neuropathy. This work also underscores the potential of repurposing established metabolic modulators for neurodegenerative disease intervention, especially where oxidative stress is a central pathological feature (Jia et al., 2025).

Comparison with Existing Internal Articles

Several recent internal reviews and guides have highlighted the translational potential of Epalrestat and related aldose reductase inhibitors in metabolic and neurodegenerative research:

• The article “Epalrestat: High-Purity Aldose Reductase Inhibitor…” details Epalrestat’s dual roles in polyol pathway inhibition and KEAP1/Nrf2 pathway activation, aligning with the mechanistic findings of Jia et al. This reinforces the reproducibility and mechanistic clarity of Epalrestat’s action across diabetic complication and neuroprotection models.
• In “Epalrestat in Translational Neurodegeneration: Mechanisms and Models”, researchers discuss assay strategies for oxidative stress research using Epalrestat, providing workflow guidance complementary to the in vivo and in vitro protocols described by Jia et al.
• Comparatively, broader polyol pathway reviews such as “Epalrestat: Aldose Reductase Inhibitor for Diabetic and N…” and “Targeting Fructose Metabolism: Implications for Cancer Therapy” situate Epalrestat within the context of metabolic reprogramming in cancer and diabetes, emphasizing the shared relevance of aldose reductase inhibitors across disease domains.

Jia et al.’s work distinguishes itself by providing direct molecular evidence for Epalrestat’s interaction with KEAP1 and its downstream effects in PD-specific models, narrowing the translational focus to neurodegeneration while building on the cross-disciplinary foundation established in internal and external literature.

Limitations and Transferability

While the results from Jia et al. are robust, several limitations should be considered:

• The study uses acute toxin-induced PD models (MPP⁺ and MPTP), which, while well-established, may not fully recapitulate the progressive nature and multifactorial etiology of human PD.
• Although direct binding and pathway activation were demonstrated, the long-term effects and safety of sustained Epalrestat use in neurodegenerative contexts remain to be addressed in future studies.
• The transferability of dosing regimens and efficacy from animal models to human patients is still uncertain and requires further clinical validation.

Nonetheless, the mechanistic clarity regarding KEAP1/Nrf2 activation provides a strong rationale for investigating Epalrestat in additional models of oxidative stress, neurodegeneration, and even metabolic disease, as supported by prior cancer metabolism research on polyol pathway inhibition.

Research Support Resources

Researchers interested in oxidative stress research, diabetic neuropathy, or Parkinson’s disease models can source high-purity Epalrestat (SKU B1743) from APExBIO. This compound is confirmed for ≥98% purity and is recommended for use in studies involving aldose reductase inhibition, polyol pathway modulation, and neuroprotection via KEAP1/Nrf2 pathway activation. Note that Epalrestat is insoluble in water and ethanol but dissolves in DMSO at ≥6.375 mg/mL with gentle warming. For best results, prepare fresh solutions as needed and store at -20°C. As always, refer to the product information for detailed handling guidance; the compound is intended for research use only.